• Something wrong with this record ?

Pharmacogenomic profile of a central European urban random population-Czech population

R. Proietti, GA. Maranho Neto, S. Kunzova, O. Lo Re, A. Ahola-Olli, J. Heliste, JP. Gonzalez-Rivas, M. Vinciguerra

. 2023 ; 18 (4) : e0284386. [pub] 20230420

Language English Country United States

Document type Observational Study, Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc23011742

The genetic basis of variability in drug response is at the core of pharmacogenomics (PGx) studies, aiming at reducing adverse drug reaction (ADR), which have interethnic variability. This study used the Kardiovize Brno 2030 random urban Czech sample population to analyze polymorphisms in a wide spectrum of genes coding for liver enzymes involved in drug metabolism. We aimed at correlating real life drug consumption with pharmacogenomic profile, and at comparing these data with the SUPER-Finland Finnish PGx database. A total of 250 individuals representative of the Kardiovize Brno 2030 cohort were included in an observational study. Blood DNA was extracted and 59 single nucleotide polymorphisms within 13 genes (BCHE, CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A5, F2, F5, IFNL3, SLCO1B1, TPMT, UGT1A1, VKORC1), associated to different drug metabolizing rates, were characterized by genotyping using a genome wide commercial array. Widely used drugs such as anti-coagulant warfarin and lipid lowering agent atorvastatin were associated to an alarmingly high percentage of users with intermediate/poor metabolism for them. Significant differences in the frequency of normal/intermediate/poor/ultrarapid/rapid metabolizers were observed for CYPD26 (p<0.001), CYP2C19 (p<0.001) and UGT1A1 (p<0.001) between the Czech and the Finnish study populations. Our study demonstrated that administration of some popular drugs to a Czech random sample population is associated with different drug metabolizing rates and therefore exposing to risk for ADRs. We also highlight interethnic differentiation of some common pharmacogenetics variants between Central (Czech) and North European (Finnish) population studies, suggesting the utility of PGx-informed prescription based on variant genotyping.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23011742
003      
CZ-PrNML
005      
20230801133310.0
007      
ta
008      
230718s2023 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1371/journal.pone.0284386 $2 doi
035    __
$a (PubMed)37079615
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Proietti, Riccardo $u Liverpool Centre for Cardiovascular Sciences (LCCS), University of Liverpool, Liverpool, United Kingdom
245    10
$a Pharmacogenomic profile of a central European urban random population-Czech population / $c R. Proietti, GA. Maranho Neto, S. Kunzova, O. Lo Re, A. Ahola-Olli, J. Heliste, JP. Gonzalez-Rivas, M. Vinciguerra
520    9_
$a The genetic basis of variability in drug response is at the core of pharmacogenomics (PGx) studies, aiming at reducing adverse drug reaction (ADR), which have interethnic variability. This study used the Kardiovize Brno 2030 random urban Czech sample population to analyze polymorphisms in a wide spectrum of genes coding for liver enzymes involved in drug metabolism. We aimed at correlating real life drug consumption with pharmacogenomic profile, and at comparing these data with the SUPER-Finland Finnish PGx database. A total of 250 individuals representative of the Kardiovize Brno 2030 cohort were included in an observational study. Blood DNA was extracted and 59 single nucleotide polymorphisms within 13 genes (BCHE, CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A5, F2, F5, IFNL3, SLCO1B1, TPMT, UGT1A1, VKORC1), associated to different drug metabolizing rates, were characterized by genotyping using a genome wide commercial array. Widely used drugs such as anti-coagulant warfarin and lipid lowering agent atorvastatin were associated to an alarmingly high percentage of users with intermediate/poor metabolism for them. Significant differences in the frequency of normal/intermediate/poor/ultrarapid/rapid metabolizers were observed for CYPD26 (p<0.001), CYP2C19 (p<0.001) and UGT1A1 (p<0.001) between the Czech and the Finnish study populations. Our study demonstrated that administration of some popular drugs to a Czech random sample population is associated with different drug metabolizing rates and therefore exposing to risk for ADRs. We also highlight interethnic differentiation of some common pharmacogenetics variants between Central (Czech) and North European (Finnish) population studies, suggesting the utility of PGx-informed prescription based on variant genotyping.
650    _2
$a lidé $7 D006801
650    12
$a farmakogenetika $7 D010597
650    _2
$a cytochrom P450 CYP2C19 $x genetika $x metabolismus $7 D065731
650    _2
$a genotyp $7 D005838
650    12
$a polymorfismus genetický $7 D011110
650    _2
$a cytochrom P-450 CYP2D6 $x genetika $7 D019389
650    _2
$a cytochrom P450 CYP2C9 $x genetika $x metabolismus $7 D065729
650    _2
$a polypeptid C přenášející organické anionty $x genetika $7 D027381
650    _2
$a vitamin K - epoxid reduktázy $x genetika $7 D064417
651    _2
$a Česká republika $7 D018153
655    _2
$a pozorovací studie $7 D064888
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Maranho Neto, Geraldo A $u International Clinical Research Center, St Anne's University Hospital, Brno, Czech Republic
700    1_
$a Kunzova, Sarka $u International Clinical Research Center, St Anne's University Hospital, Brno, Czech Republic
700    1_
$a Lo Re, Oriana $u International Clinical Research Center, St Anne's University Hospital, Brno, Czech Republic $u Department of Stem Cell Biology and Transplantology, Research Institute of the Medical University of Varna (RIMUV), Varna, Bulgaria
700    1_
$a Ahola-Olli, Ari $u Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland $u Stanley Center for Psychiatric Research, The Broad Institute of MIT (Massachusetts Institute of Technology) and Harvard University, Cambridge, MA, United States of America
700    1_
$a Heliste, Juho $u Institute of Biomedicine, University of Turku, Turku, Finland
700    1_
$a Gonzalez-Rivas, Juan Pablo $u International Clinical Research Center, St Anne's University Hospital, Brno, Czech Republic $u Harvard T.H. Chan School of Public Health, Harvard University, Cambridge, MA, United States of America
700    1_
$a Vinciguerra, Manlio $u International Clinical Research Center, St Anne's University Hospital, Brno, Czech Republic $u Department of Stem Cell Biology and Transplantology, Research Institute of the Medical University of Varna (RIMUV), Varna, Bulgaria $u Liverpool Centre for Cardiovascular Sciences (LCCS), Liverpool John Moores University, Liverpool, United Kingdom $1 https://orcid.org/0000000217683894
773    0_
$w MED00180950 $t PloS one $x 1932-6203 $g Roč. 18, č. 4 (2023), s. e0284386
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37079615 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230718 $b ABA008
991    __
$a 20230801133307 $b ABA008
999    __
$a ok $b bmc $g 1963908 $s 1198007
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 18 $c 4 $d e0284386 $e 20230420 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
LZP    __
$a Pubmed-20230718

Find record

Citation metrics

Archiving options